

February 27, 2014



Pressure BioSciences, Inc. to Present at the NIBA Florida Investment Conference

SOUTH EASTON, Mass., Feb. 27, 2014 /PRNewswire/ -- Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced that Mr. Richard T. Schumacher, President and CEO, will present a corporate overview and business update at the Florida Investment Conference of the National Investment Banking Association ("NIBA"). The NIBA Investment Conference is being held from February 26-28 at the Riverside Hotel in Ft. Lauderdale, Florida. Mr. Schumacher is scheduled to present today (February 27th) at 2:50 pm EST in the Himarshee Ballroom.

About the National Investment Banking Association (NIBA)

The National Investment Banking Association (NIBA) is a national trade association of regional and independent brokerages, investment banking firms, and related capital market service providers. The mission of NIBA is to add value to its members, their client companies and investors, and the securities industry at large by continuing to be the premier forum for quality micro-cap/small cap companies seeking access and exposure to the financial community and to be the focal point for all those seeking to enhance the financial environment for small companies.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) is focused on the development, marketing, and sale of proprietary laboratory instrumentation and associated consumables based on Pressure Cycling Technology ("PCT"). PCT is a patented, enabling technology platform with multiple applications in the estimated \$6 billion life sciences sample preparation market. PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. PBI currently focuses its efforts on the development and sale of PCT-enhanced sample preparation systems (instruments and consumables) for biomarker discovery and forensics, and for bio-therapeutics characterization, vaccine development, soil and plant biology, histology, and counter-bioterror applications.

For more information about PBI and this press release, please click on the following website link: <http://www.pressurebiosciences.com>

Please Visit us on Facebook, LinkedIn, and Twitter

Investor Contacts:	
Richard T. Schumacher, President and CEO	(508) 230-1828 (T)
Richard P. Thomley, Acting CFO	(508) 230-1829 (F)

SOURCE Pressure BioSciences, Inc.